A5034068291- Pharmacogenetics and Drug Metabolism
- Cancer Treatment and Pharmacology
- Pharmaceutical studies and practices
- Pharmaceutical Practices and Patient Outcomes
- Inflammatory mediators and NSAID effects
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Computational Drug Discovery Methods
- Medication Adherence and Compliance
- Microtubule and mitosis dynamics
- Pharmacology and Obesity Treatment
- Complementary and Alternative Medicine Studies
- Cardiovascular Syncope and Autonomic Disorders
- Peripheral Neuropathies and Disorders
- Colorectal Cancer Treatments and Studies
- Transplantation: Methods and Outcomes
- 14-3-3 protein interactions
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Hematopoietic Stem Cell Transplantation
- Adrenal Hormones and Disorders
- Drug Transport and Resistance Mechanisms
- Hereditary Neurological Disorders
- Renal Transplantation Outcomes and Treatments
- Eicosanoids and Hypertension Pharmacology
Mercer Island School District
2024
Washington State University Spokane
2019-2021
Washington State University
2020
University of Michigan
2017-2019
Purpose: Patients with cancer are an especially vulnerable population to potential drug-drug interactions (DDIs). This makes it important adequately screen them for DDIs. The objective of this study was compare the abilities nine DDI screening tools detect clinically relevant oral oncolytics. Methods: Subscription-based (ie, PEPID, Micromedex, Lexicomp, Facts & Comparisons) and free Epocrates Free, Medscape, Drugs.com, RxList, WebMD) were compared their DDIs 145 drug pairs including...
Drug-drug interactions (DDIs) in subjects enrolling clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen manage DDIs. The objective was determine prevalence DDIs involving medications National Clinical Trials Network (NCTN) at a single institution. were evaluated based on protocol recommendations for concomitant medication use (i.e. exclude, avoid or caution), screening via DDI tool, pharmacist...
Aim: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [Tc >0.05]). Second, screen additional pharmacogenes for associations with Tc >0.05. Methods: Pharmacogene panel genotypes were translated into genetic phenotypes >0.05 (n = 58). Results: Patients predicted low-activity had shorter after adjustment age, body surface area and race (9.65 vs 11.03 hrs, β 5.47, p 0.02). This...
Aims Chemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation ( EPHA4 , EPHA5 EPHA6 and EPHA8 ) associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold). Methods Germline DNA from 60 patients breast cancer was sequenced. measured using the 8‐item sensory subscale (CIPN8) patient‐reported CIPN20. Associations 3 models were tested incorporating genetics into...
Tamoxifen bioactivation to endoxifen is mediated primarily by CYP2D6; however, considerable variability remains unexplained. Our aim was perform a comprehensive assessment of the effect genetic variation in tamoxifen-relevant enzymes and transporters on steady-state concentrations.Comprehensive genotyping CYP performed using iPLEX ADME PGx Pro Panel 302 tamoxifen-treated breast cancer patients. Predicted activity phenotype for 19 were analyzed univariate association with concentration, then...
CYP2D6 is a highly polymorphic gene with clinically important structural variations. Commonly, only exon 9 assayed on clinical pharmacogenomics panels, as it allows for accurate functional characterization even in the presence of CYP2D6::CYP2D7 conversion. However, this method does not capture CYP2D7::CYP2D6 (CYP2D6*13) conversions, possibly leading to inaccurate phenotype assignment. The study’s purpose was determine frequency variations utilizing multiple copy number variation (CNV) assay...
Introduction Patients with cancer are increasingly using herbal supplements, unaware that supplements can interact oncology treatment. Herb–drug interaction management is critical to ensure optimal treatment outcomes. Several screening tools exist detect drug–drug interactions, but their performance herb–drug interactions not known. This study compared the of eight anti-cancer agents. Methods The detection four subscription (Micromedex, Lexicomp, PEPID, Facts & Comparisons) and free...
Aim: This study explored whether inherited variants in genes causing the hereditary neuropathy condition Charcot–Marie–Tooth disease are associated with sensitivity to paclitaxel-induced peripheral (PN). Patients & methods: Hereditary previously risk of PN were sequenced paclitaxel-treated patients. Eight putative genetic predictors five (ARHGEF10, SBF2, FGD4, FZD3 and NXN) tested for association after accounting systemic exposure clinical variables. Results: rs7833751, a proxy rs7001034,...
CYP3A5 and CYP3A4 are the predominant enzymes responsible for tacrolimus metabolism; however only a proportion of population expresses secondary to genetic variation. is expressed in both intestine liver has been shown impact bioavailability metabolism orally administered tacrolimus. Increasing initial dose by 50% 100% recommended patients who known expressers; however, whether this adjustment appropriate i.v. administration unclear. The objective study was evaluate genotype as well other...
Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial subjects ensure subject safety and data accuracy. This study determined the prevalence potential involving oral anti-cancer agents enrolled two SWOG trials.Completed trials commercially available possible that had complete concomitant medication information enrollment were...
Background: Tamoxifen, as a treatment of estrogen receptor positive (ER+) breast cancer, is weak anti-estrogen that requires metabolic activation to form metabolites with higher anti-estrogenic activity. Endoxifen the most-studied active tamoxifen metabolite, and endoxifen concentrations are highly associated CYP2D6 Associations efficacy measured or CYP2D6-predicted have been inconclusive. Another 4-OHtam, other, less metabolites, Z-4′-endoxifen Z-4′-OHtam, also reported be efficacy. Method:...
315 Background: Screening drug-drug interactions (DDI) for subjects enrolling in oncology clinical trials is critical to ensuring patient safety and the validity of trial data. We previously reported that DDI screening not uniformly conducted when patients enrollment into SWOG found at University Michigan Rogel Cancer Center up 24.2% enrolled National Clinical Trial Network (NCTN) had a DDI. tools aid reduction practice, but none have been created enrollment. Our objective was develop...
532 Background: Chemotherapy induced peripheral neuropathy (CIPN) is a common, debilitating paclitaxel side effect that has been primarily attributed to cumulative systemic exposure. Paclitaxel dose-adjustment achieve target exposure decreases but does not eliminate severe CIPN, suggesting some patients are inherently CIPN-sensitive. Ephrin ( EPHA) polymorphisms have reported increase CIPN occurrence (Baldwin 2012, Leandro-Garcia 2013, Boora 2016) replication challenging, perhaps due the...
Objectives Screening subjects for drug-drug interactions (DDIs) before enrollment in oncology clinical trials is integral to ensuring safety, but standard procedures or tools are not readily available screen DDI this setting. Our objectives were develop a screening tool use during trial and test usability single-center multicenter pilot studies. Methods A multistage approach was used quality improvement intervention. Semistructured interviews with individuals responsible conducted prototype...
e18819 Background: Oncology patients are at high risk of clinically relevant drug-drug interactions (DDIs) due to rates polypharmacy. DDIs in enrolled clinical trials can adversely affect patient safety, study drug outcomes and validity. The objective was determine the prevalence involving drugs NCTN University Michigan Comprehensive Cancer Center (UMCCC). Methods: All commercially available medications UMCCC from January 2013 August 2017 were included. Patient’s concomitant medication lists...